TrialNature communications2025

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Dean A Fennell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.